Akebia Therapeutics, Inc. Exhibit
EX-99.1 2 d685250dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights – Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance – – First regulatory submission for vadadustat expected in 2019 in Japan,…
To view the full exhibit click here

About AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.